Article Information
History
- July 7, 2021.
Article Versions
- You are currently viewing Version 1 of this article (July 7, 2021 - 22:07).
- Version 2 (July 11, 2021 - 12:25).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Manuela Jaklin1,2,4,#,*,
- Jitao David Zhang1,*,#,
- Nicole Schäfer1,
- Nicole Clemann1,
- Paul Barrow1,
- Erich Küng1,
- Lisa Sach-Peltason1,
- Claudia McGinnis3,
- Marcel Leist2 and
- Stefan Kustermann1
- 1Pharma Research and Early Development, Roche Innovation Centre Basel, F. Hoffmann - La Roche, Switzerland
- 2Department for In Vitro Toxicology and Biomedicine Inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Germany
- 3University of Dundee, Drug Discovery Unit, Dundee, Scotland, UK
- 4Weleda AG, Arlesheim, Switzerland
- ↵#To whom correspondence should be addressed: mail.manuela.jaklin{at}gmail.com (MJ), jitao_david.zhang{at}roche.com (JDZ).
↵* these authors contributed equally